Lonza Group AG Logo

Lonza Group AG

A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.

LONN | SW

Overview

Corporate Details

ISIN(s):
CH0013841017 (+2 more)
LEI:
549300EFW4H2TCZ71055
Country:
Switzerland
Address:
MÜNCHENSTEINERSTR. 38, 4052 BASEL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lonza Group AG is a Swiss multinational company and a leading global Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical, biotechnology, and nutrition industries. The company provides integrated services that span from early-stage development to the commercial manufacturing of drug substances and drug products. Lonza specializes in a wide range of advanced technologies, including mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, and cell and gene therapies. Founded in 1897, Lonza leverages its extensive scientific and manufacturing expertise to enable its customers to bring innovative and life-enhancing therapies to market for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 06:30
Earnings Release
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 18.3 KB
2025-10-23 02:00
Earnings Release
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 15.5 KB
2025-10-03 09:00
Board/Management Information
Lonza Nominates Claudia Sussmuth-Dyckerhoff as Board Member
English 17.8 KB
2025-10-03 02:00
Board/Management Information
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
English 14.2 KB
2025-09-12 09:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 22.8 KB
2025-09-12 02:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 18.8 KB
2025-07-23 06:30
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 42.2 KB
2025-07-23 02:00
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 37.0 KB
2025-07-23 02:00
Earnings Release
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
German 36.9 KB
2025-05-27 07:00
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 12.7 KB
2025-05-27 02:00
Regulatory News Service
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 9.7 KB
2025-05-15 09:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 14.6 KB
2025-05-15 02:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 11.0 KB
2025-05-10 16:30
Post-Annual General Meeting Information
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
English 16.3 KB
2025-05-09 06:30
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
English 15.2 KB

Automate Your Workflow. Get a real-time feed of all Lonza Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lonza Group AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lonza Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 N/A Executive member Buy None 147,442.00 CHF
2025-03-13 N/A Executive member Buy None 107,906.00 CHF
2025-03-12 N/A Executive member Buy None 146,239.00 CHF
2025-03-11 N/A Executive member Buy None 382,476.00 CHF
2025-03-10 N/A Executive member Buy None 771,722.40 CHF
2025-03-07 N/A Executive member Buy None 338,476.00 CHF
2025-03-06 N/A Executive member Buy None 313,416.00 CHF
2025-02-18 N/A Executive member Buy None 164,554.00 CHF
2025-02-14 N/A Executive member Buy None 130,606.00 CHF
2025-02-13 N/A Executive member Buy None 29,500.00 CHF

Peer Companies

Benitec Biopharma Inc. Logo
Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Develops innovative and accessible cancer treatments for patients worldwide.
United States of America
ONC
BGM Group Ltd. Logo
A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea
238200
BioAge Labs, Inc. Logo
Develops therapies for metabolic diseases like obesity by targeting the biology of human aging.
United States of America
BIOA
BioArctic Logo
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
Sweden
BIOA
BioAtla, Inc. Logo
Developing safer, conditionally active antibody therapies for solid tumor cancers.
United States of America
BCAB
BioCardia, Inc. Logo
Developing regenerative cell therapies for cardiovascular and pulmonary diseases.
United States of America
BCDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.